Evaluation of Pathologic Complete Response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on pCR | Zendy

Ramesh Omranipour | Zendy; Roghiyeh Jalili | Zendy; Adel Yazdankhahkenary | Zendy; Abdolali Assarian | Zendy; Mehrzad Mirzania | Zendy; Bita Eslami | Zendy

Open Access

Evaluation of Pathologic Complete Response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on pCR

Author(s) -

Ramesh Omranipour,

Roghiyeh Jalili,

Adel Yazdankhahkenary,

Abdolali Assarian,

Mehrzad Mirzania,

Bita Eslami

Publication year - 2020

Publication title -

meme sağlığı dergisi/meme sağlığı dergisi

Language(s) - English

Resource type - Journals

eISSN - 1306-0953

pISSN - 1306-0945

DOI - 10.5152/ejbh.2020.5487

Subject(s) - breast cancer , medicine , oncology , estrogen receptor , neoadjuvant therapy , lymph node , receiver operating characteristic , chemotherapy , axillary lymph nodes , progesterone receptor , cancer

The pathologic complete response (pCR) in the breast and axillary lymph node after neoadjuvant chemotherapy (NAC) would improve outcomes and it is used as a surrogate marker for survival. Our objective was to evaluate the breast and nodal pCR in breast cancer patients with estrogen receptor-positive (ER) and HER2 negative subtypes. Meanwhile, we sought to examine the impact of predicting factors on the rate of pCR.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research